Incorporation of Hydrophilic Macrocycles Into Drug-Linker Reagents Produces Antibody-Drug Conjugates With Enhanced in vivo Performance

Antibody-drug conjugates (ADCs) have begun to fulfil their promise as targeted cancer therapeutics with ten clinical approvals to date. As the field matures, much attention has focused upon the key factors required to produce safe and efficacious ADCs. Recently the role that linker-payload reagent d...

Descripción completa

Detalles Bibliográficos
Autores principales: Evans, Nick, Grygorash, Ruslan, Williams, Paul, Kyle, Andrew, Kantner, Terrence, Pathak, Ravindra, Sheng, XiaoBo, Simoes, Fabio, Makwana, Hiteshri, Resende, Ricardo, de Juan, Elena, Jenkins, Alan, Morris, David, Michelet, Aurelie, Jewitt, Frances, Rudge, Felicity, Camper, Nicolas, Manin, Anaïs, McDowell, William, Pabst, Martin, Godwin, Antony, Frigerio, Mark, Bird, Matthew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247464/
https://www.ncbi.nlm.nih.gov/pubmed/35784686
http://dx.doi.org/10.3389/fphar.2022.764540

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247464/
https://www.ncbi.nlm.nih.gov/pubmed/35784686
http://dx.doi.org/10.3389/fphar.2022.764540

Ejemplares similares